Axitinib/Axitinib Tablets Usage and Dosage Guidelines

Axitinib/Axitinib (Axitinib) is a targeted therapy drug commonly used to treat malignant tumors such as advanced renal cell carcinoma (RCC). It inhibits the VEGFR signaling pathway and reduces the blood supply to tumors, thereby inhibiting tumor growth. Axitinib is usually taken orally in tablet form, with clear dosing and administration guidelines to ensure the safety and effectiveness of the treatment.

During treatment, the dose of axitinib needs to be adjusted based on the patient's tolerance and treatment response. For treatment regimens that combine axitinib with an immune checkpoint inhibitor (such as avelumab or pembrolizumab), the recommended starting dose is usually 5 mg orally twice daily, 12 hours apart. When used together, the dose of axitinib can be increased as needed, especially if the patient is able to tolerate higher doses. For example, when coadministered with avelumab, patients may consider increasing the dose of axitinib above the initial dose of 10 mg every two weeks along with avelumab.

In the setting of monotherapy, the recommended starting dose of axitinib is 5 mg twice daily 12 hours apart. Patients should take the tablets at their regular time, swallowing them whole with water and not chewing or crushing the tablets. If a patient misses a dose during treatment, they should not take the missed dose but continue with the next dose at the normal time. It should be noted that the dose of axitinib should be dynamically adjusted according to the patient's blood pressure, liver function and other conditions. Some patients may experience side effects such as hypertension and abnormal liver function, in which case the dose needs to be adjusted based on clinical response.

The duration of axitinib use is usually determined based on the progression of the disease. In combination therapy, treatment can be continued until disease progression or unacceptable toxicity occurs. In monotherapy, the duration of treatment is usually assessed based on tumor control. If the patient experiences serious adverse reactions during treatment, such as high blood pressure, liver damage, bleeding, etc., the drug may need to be temporarily discontinued or the dosage adjusted until the side effects are relieved.

Reference materials:https://en.wikipedia.org/wiki/Axitinib